In vivo reprogramming in inflammatory bowel disease

Gene Therapy

Volumn 20, Issue 12, 2013, Pages 1111-1118

  Wagnerova, A ^a   Gardlik, R ^a  

^a Bratislava   (Slovakia)

Author keywords

bacterial vectors; in vivo; inflammatory bowel disease; pluripotency; stem cells

Indexed keywords

AZATHIOPRINE; BACTERIAL VECTOR; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; INTERLEUKIN 10; KRUPPEL LIKE FACTOR 5; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OLSALAZINE;

ADULT STEM CELL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BACTERIAL VIRULENCE; CELL DIFFERENTIATION; CELL REGENERATION; CROHN DISEASE; EMBRYONIC STEM CELL; ENTEROENDOCRINE CELL; ENVIRONMENTAL FACTOR; EX VIVO GENE TRANSFER; GENETIC ENGINEERING; GOBLET CELL; HUMAN; IN VIVO GENE TRANSFER; INNATE IMMUNITY; INTESTINE CELL; INTESTINE FLORA; INTESTINE RESECTION; LACTOBACILLUS ACIDOPHILUS; LACTOCOCCUS LACTIS; MICROCIRCULATION; MICROENVIRONMENT; NONHUMAN; NUCLEAR REPROGRAMMING; PANETH CELL; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; REVIEW; SALMONELLA TYPHIMURIUM; SOMATIC CELL; ULCERATIVE COLITIS;

BACTERIA (MICROORGANISMS);

ANIMALS; BACTERIA; CELL DIFFERENTIATION; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; NUCLEAR REPROGRAMMING;

EID: 84890122473     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2013.43     Document Type: Review

References (100)

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126: 663-676.
2. Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 2007; 25: 1177-1181.
3. Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K et al. Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science 2008; 321: 699-702.
4. Eminli S, Utikal J, Arnold K, Jaenisch R, Hochedlinger K. Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. Stem Cells 2008; 26: 2467-2474.
5. Hanna J, Markoulaki S, Schorderet P, Carey BW, Beard C, Wernig M et al. Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. Cell 2008; 133: 250-264.
6. Aasen T, Raya A, Barrero MJ, Garreta E, Consiglio A, Gonzalez F et al. Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 2008; 26: 1276-1284.
7. Seki T, Yuasa S, Oda M, Egashira T, Yae K, Kusumoto D et al. Generation of induced pluripotent stem cells from human terminally differentiated circulating T cells. Cell Stem Cell 2010; 7: 11-14.
8. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007; 131: 861-872.
9. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-1920.
10. Lai MI, Wendy-Yeo WY, Ramasamy R, Nordin N, Rosli R, Veerakumarasivam A et al. Advancements in reprogramming strategies for the generation of induced pluripotent stem cells. J Assist Reprod Genet 2011; 28: 291-301.
11. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2008; 26: 101-106.
12. Huangfu D, Osafune K, Maehr R, Guo W, Eijkelenboom A, Chen S et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol 2008; 26: 1269-1275.
13. Kim JB, Greber B, Arauzo-Bravo MJ, Meyer J, Park KI, Zaehres H et al. Direct reprogramming of human neural stem cells by OCT4. Nature 2009; 461: 649-643.
14. Miyazaki S, Yamamoto H, Miyoshi N, Takahashi H, Suzuki Y, Haraguchi N et al. Emerging methods for preparing iPS cells. Jpn J Clin Oncol 2012; 42: 773-779.
15. Leonardo TR, Schultheisz HL, Loring JF, Laurent LC. The functions of microRNAs in pluripotency and reprogramming. Nat Cell Biol 2012; 14: 1114-1121.
16. Blelloch R, Venere M, Yen J, Ramalho-Santos M. Generation of induced pluripotent stem cells in the absence of drug selection. Cell Stem Cell 2007; 1: 245-247.
17. Brambrink T, Foreman R, Welstead GG, Lengner CJ, Wernig M, Suh H et al. Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. Cell Stem Cell 2008; 2: 151-159.
18. Maherali N, Ahfeldt T, Rigamonti A, Utikal J, Cowan C, Hochedlinger K. A highefficiency system for the generation and study of human induced pluripotent stem cells. Cell Stem Cell 2008; 3: 340-345.
19. Maherali N, Hochedlinger K. Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008; 3: 595-605.
20. Riggs JW, Barrilleaux BL, Varlakhanova N, Bush KM, Chan V, Knoepfler PS. Induced pluripotency and oncogenic transformation are related processes. Stem Cells Dev 2013; 22: 37-50.
21. Kim D, Kim CH, Moon JI, Chung YG, Chang MY, Han BS et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell 2009; 4: 472-476.
22. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T et al. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009; 4: 381-384.
23. Okita K, Hong H, Takahashi K, Yamanaka S. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc 2010; 5: 418-428.
24. Gonzalez F, Barragan Monasterio M, Tiscornia G, Montserrat Pulido N, Vassena R, Batlle Morera L et al. Generation of mouse-induced pluripotent stem cells by transient expression of a single nonviral polycistronic vector. Proc Natl Acad Sci USA 2009; 106: 8918-8922.
25. Li W, Wei W, Zhu S, Zhu J, Shi Y, Lin T et al. Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. Cell Stem Cell 2009; 4: 16-19.
26. Shi Y, Desponts C, Do JT, Hahm HS, Scholer HR, Ding S. Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with smallmolecule compounds. Cell Stem Cell 2008; 3: 568-574.
27. Huangfu D, Maehr R, Guo W, Eijkelenboom A, Snitow M, Chen AE et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol 2008; 26: 795-797.
28. Feng B, Ng JH, Heng JC, Ng HH. Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. Cell Stem Cell 2009; 4: 301-312.
29. Kang L, Wang J, Zhang Y, Kou Z, Gao S. iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. Cell Stem Cell 2009; 5: 135-138.
30. Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T et al. iPS cells produce viable mice through tetraploid complementation. Nature 2009; 461: 86-90.
31. Boland MJ, Hazen JL, Nazor KL, Rodriguez AR, Gifford W, Martin G et al. Adult mice generated from induced pluripotent stem cells. Nature 2009; 461: 91-94.
32. Zhao XY, Li W, Lv Z, Liu L, Tong M, Hai T et al. Viable fertile mice generated from fully pluripotent iPS cells derived from adult somatic cells. Stem Cell Rev 2010; 6: 390-397.
33. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007; 448: 313-317.
34. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007; 448: 318-324.
35. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007; 2: 3081-3089.
36. Marti M, Mulero L, Pardo C, Morera C, Carrio M, Laricchia-Robbio L et al. Characterization of pluripotent stem cells. Nat Protoc 2013; 8: 223-253.
37. Vitale AM, Wolvetang E, Mackay-Sim A. Induced pluripotent stem cells: A new technology to study human diseases. Int J Biochem Cell Biol 2011; 43: 843-846.
38. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A et al. Disease-specific induced pluripotent stem cells. Cell 2008; 134: 877-886.
39. Bellin M, Marchetto MC, Gage FH, Mummery CL. Induced pluripotent stem cells: The new patient? Nat Rev Mol Cell Biol 2012; 13: 713-726.
40. Gao A, Peng Y, Deng Y, Qing H. Potential therapeutic applications of differentiated induced pluripotent stem cells (iPSCs) in the treatment of neurodegenerative diseases. Neuroscience 2013; 228: 47-59.
41. Anchan RM, Quaas P, Gerami-Naini B, Bartake H, Griffin A, Zhou Y et al. Amniocytes can serve a dual function as a source of iPS cells and feeder layers. Hum Mol Genet 2011; 20: 962-974.
42. Wong GK, Chiu AT. Gene therapy, gene targeting and induced pluripotent stem cells: Applications in monogenic disease treatment. Biotechnol Adv 2010; 28: 715-724.
43. Zwi-Dantsis L, Gepstein L. Induced pluripotent stem cells for cardiac repair. Cell Mol Life Sci 2012; 69: 3285-3299.
44. Zhu Y, Wan S, Zhan RY. Inducible pluripotent stem cells for the treatment of ischemic stroke: Current status and problems. Rev Neurosci 2012; 23: 393-402.
45. Ito D, Okano H, Suzuki N. Accelerating progress in induced pluripotent stem cell research for neurological diseases. Ann Neurol 2012; 72: 167-174.
46. Kao DI, Chen S. Pluripotent stem cell-derived pancreatic beta-cells: Potential for regenerative medicine in diabetes. Regen Med 2012; 7: 583-593.
47. Oyama Y, Craig RM, Traynor AE, Quigley K, Statkute L, Halverson A et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005; 128: 552-563.
48. Burt RK, Traynor A, Oyama Y, Craig R. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 2003; 101: 2064-2066.
49. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 2009; 136: 978-989.
50. Liang L, Dong C, Chen X, Fang Z, Xu J, Liu M et al. Human umbilical cord mesenchymal stem cells ameliorate mice trinitrobenzene sulfonic acid (TNBS)-induced colitis. Cell Transplant 2011; 20: 1395-1408.
51. Zhou Q, Price DD, Dreher KL, Pronold B, Callam CS, Sharma J et al. Localized colonic stem cell transplantation enhances tissue regeneration in murine colitis. J Cell Mol Med 2012; 16: 1900-1915.
52. Logan RF. Inflammatory bowel disease incidence: Up, down or unchanged? Gut 1998; 42: 309-311.
53. Russel MG. Changes in the incidence of inflammatory bowel disease: What does it mean? Eur J Intern Med 2000; 11: 191-196.
54. Gramlich T, Petras RE. Pathology of inflammatory bowel disease. Semin Pediatr Surg 2007; 16: 154-163.
55. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: Current practices and recent advances. Transl Res 2012; 159: 313-325.
56. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. Nat Protoc 2007; 2: 541-546.
57. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin Immunol 2004; 110: 55-62.
58. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994; 107: 1643-1652.
59. Podolsky DK. The future of IBD treatment. J Gastroenterol 2003; 38(Suppl 15): 63-66.
60. Triantafillidis JK, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Devel Ther 2011; 5: 185-210.
61. Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy: Current state-of-the-art. Curr Opin Gastroenterol 2011; 27: 346-357.
62. Buchanan J, Wordsworth S, Ahmad T, Perrin A, Vermeire S, Sans M et al. Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. J Crohns Colitis 2011; 5: 301-316.
63. Thompson-Chagoyan OC, Maldonado J, Gil A. Aetiology of inflammatory bowel disease (IBD): Role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr 2005; 24: 339-352.
64. Matsumoto S, Hara T, Hori T, Mitsuyama K, Nagaoka M, Tomiyasu N et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 2005; 140: 417-426.
65. Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, Falk W et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289: 1352-1355.
66. Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005; 100: 1539-1546.
67. Hoentjen F, Welling GW, Harmsen HJ, Zhang X, Snart J, Tannock GW et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis 2005; 11: 977-985.
68. Kanauchi O, Suga T, Tochihara M, Hibi T, Naganuma M, Homma T et al. Treatment of ulcerative colitis by feeding with germinated barley foodstuff: First report of a multicenter open control trial. J Gastroenterol 2002; 37(Suppl 14): 67-72.
69. Palffy R, Behuliak M, Gardlik R, Jani P, Kadasi L, Turna J et al. Oral in vivo bactofection in dextran sulfate sodium treated female Wistar rats. Folia Biol 2010; 58: 171-176.
70. Palffy R, Gardlik R, Behuliak M, Jani P, Balakova D, Kadasi L et al. Salmonellamediated gene therapy in experimental colitis in mice. Exp Biol Med 2011; 236: 177-183.
71. Khalil PN, Weiler V, Nelson PJ, Khalil MN, Moosmann S, Mutschler WE et al. Nonmyeloablative stem cell therapy enhances microcirculation and tissue regeneration in murine inflammatory bowel disease. Gastroenterology 2007; 132: 944-954.
72. Duijvestein M, van den Brink GR, Hommes DW. Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. J Crohns Colitis 2008; 2: 99-106.
73. Nemoto Y, Kanai T, Takahara M, Oshima S, Nakamura T, Okamoto R et al. Bone marrow-mesenchymal stem cells are a major source of interleukin-7 and sustain colitis by forming the niche for colitogenic CD4 memory T cells. Gut 2012; 62: 1142-1152.
74. Guo Y, Lu N, Bai A. Treatment of inflammatory bowel disease with neural stem cells expressing choline acetyltransferase. Med Hypotheses 2012; 79: 627-629.
75. Yin JA, Jowitt SN. Resolution of immune-mediated diseases following allogeneic bone marrow transplantation for leukaemia. Bone Marrow Transplant 1992; 9: 31-33.
76. Tyndall A, Passweg J, Gratwohl A. Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 2001; 60: 702-707.
77. Filareto A, Parker S, Darabi R, Borges L, Iacovino M, Schaaf T et al. An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nat Commun 2013; 4: 1549.
78. Yang J, Lam DH, Goh SS, Lee EX, Zhao Y, Tay FC et al. Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model. Stem Cells 2012; 30: 1021-1029.
79. Tedesco FS, Gerli MF, Perani L, Benedetti S, Ungaro F, Cassano M et al. Transplantation of genetically corrected human iPSC-derived progenitors in mice with limb-girdle muscular dystrophy. Sci Transl Med 2012; 4: 140ra189.
80. Buccini S, Haider KH, Ahmed RP, Jiang S, Ashraf M. Cardiac progenitors derived from reprogrammed mesenchymal stem cells contribute to angiomyogenic repair of the infarcted heart. Basic Res Cardiol 2012; 107: 301.
81. How CK, Chien Y, Yang KY, Shih HC, Juan CC, Yang YP et al. Induced pluripotent stem cells mediate the release of interferon gamma-induced protein 10 and alleviate bleomycin-induced lung inflammation and fibrosis. Shock 2013; 39: 261-270.
82. Gomi M, Takagi Y, Morizane A, Doi D, Nishimura M, Miyamoto S et al. Functional recovery of the murine brain ischemia model using human induced pluripotent stem cell-derived telencephalic progenitors. Brain Res 2012; 1459: 52-60.
83. Wang A, Sander M. Generating cells of the gastrointestinal system: Current approaches and applications for the differentiation of human pluripotent stem cells. J Mol Med (Berl) 2012; 90: 763-771.
84. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K et al. Directed differentiation of human pluripotent stem cells into intestinal tissue in vitro. Nature 2011; 470: 105-109.
85. Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G et al. Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet 2009; 41: 968-976.
86. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K et al. Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol 2009; 27: 743-745.
87. Hanley J, Rastegarlari G, Nathwani AC. An introduction to induced pluripotent stem cells. Br J Haematol 2010; 151: 16-24.
88. Gardlik R. Inducing pluripotency using in vivo gene therapy. Med Hypotheses 2012; 79: 197-201.
89. Sheng X, Reppel M, Nguemo F, Mohammad FI, Kuzmenkin A, Hescheler J et al. Human pluripotent stem cell-derived cardiomyocytes: Response to TTX and lidocain reveals strong cell to cell variability. PLoS One 2012; 7: E45963.
90. Giuliani M, Oudrhiri N, Noman ZM, Vernochet A, Chouaib S, Azzarone B et al. Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood 2011; 118: 3254-3262.
91. Yamada S, Nelson TJ, Behfar A, Crespo-Diaz RJ, Fraidenraich D, Terzic A. Stem cell transplant into preimplantation embryo yields myocardial infarction-resistant adult phenotype. Stem Cells 2009; 27: 1697-1705.
92. Palffy R, Gardlik R, Hodosy J, Behuliak M, Resko P, Radvansky J et al. Bacteria in gene therapy: Bactofection versus alternative gene therapy. Gene Therapy 2006; 13: 101-105.
93. Gardlik R, Fruehauf JH. Bacterial vectors and delivery systems in cancer therapy. IDrugs 2010; 13: 701-706.
94. Foligne B, Dessein R, Marceau M, Poiret S, Chamaillard M, Pot B et al. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 2007; 133: 862-874.
95. Vandenbroucke K, De Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2010; 3: 49-56.
96. Gardlik R, Bartonova A, Celec P. Therapeutic DNA vaccination and RNA interference in inflammatory bowel disease. Int J Mol Med 2013; 32: 492-496.
97. Hamady ZZ, Scott N, Farrar MD, Lodge JP, Holland KT, Whitehead T et al. Xylan-regulated delivery of human keratinocyte growth factor-2 to the inflamed colon by the human anaerobic commensal bacterium Bacteroides ovatus. Gut 2010; 59: 461-469.
98. Ohta K, Kawano R, Ito N. Lactic acid bacteria convert human fibroblasts to multipotent cells. PLoS One 2012; 7: E51866.
99. Finkbeiner SR, Spence Jr. A gutsy task: Generating intestinal tissue from human pluripotent stem cells. Dig Dis Sci 2013; 58: 1176-1184.
100. Fujii Y, Yoshihashi K, Suzuki H, Tsutsumi S, Mutoh H, Maeda S et al. CDX1 confers intestinal phenotype on gastric epithelial cells via induction of stemnessassociated reprogramming factors SALL4 and KLF5. Proc Natl Acad Sci USA 2012; 109: 20584-20589.